Amgen TEZSPIRE Shows Promising Results in Eosinophilic Esophagitis: Could It Transform Treatment for Patients with Swallowing Difficulties?

The pharmaceutical industry is increasingly focusing on targeted biologic therapies to address chronic inflammatory diseases that remain difficult to manage with conventional treatments. As scientific understanding with conventional treatments. As scientific understanding if immune pathways advances, pharmaceutical companies are exploring new approaches that could improve disease control and patient quality of life.

On October 20, 2026, Amgen and AstraZeneca announced positive results from the Phase 3 CROSSING trial evaluating TEZSPIRE in adolescents and adults with symptomatic, uncontrolled eosinophilic esophagitis (EoE). The study demonstrated statistically significant improvements in histologic remission and swallowing symptoms, with benefits sustained through 52 weeks. The finding highlights the potential of targeted inflammation control to address an important unmet need in gastrointestinal care. However, TEZSPIRE remains under development for EoE, and the reported results do not mean it is approved for this condition.

TEZSPIRE Demonstrates Significant Improvements in Disease Control

The CROSSING trial evaluated TEZSPIRE at two doses, 210 mg and 420 mg, administered through subcutaneous injections every four weeks. The randomized, double-blind, placebo-controlled study enrolled 368 patients aged 12 to80 years with symptomatic and histologically active EoE.

At week 24, histologic remission was achieved by 64.8% of patients receiving the 210 mg dose and 68.9% receiving the 420 mg dose. In comparison, only 3.5% of patients in the placebo group achieved remission. These differences were statistically significant.

Histological remission measures the reduction of eosinophils in esophageal cells associated with inflammation in esophageal tissue. In this trial, remission was defined as a peak eosinophil count of six or fewer per high-power microscopic field.

The treatment also improved swallowing symptoms, including the frequency and severity of dysphagia. Improvements were measured using the Dysphagia Symptoms Questionnaire, a patient-reported assessment of swallowing difficulties.

At week 24, average symptom scores decreased by 18.8 points with the 210 mg dose and 22.0 points with the 420 my dose, compared with 14.7 points in the placebo group. The results indicate that TEZSPIRE may help address both underlying inflammation and the daily symptoms experienced by patients.

Benefits Sustained Through 52 Weeks

One of the most important findings from the CRPSSING trial was that improvements in disease control continued through week 52. This suggests that TEZSPINE could potentially offer sustained benefits for patients who require long-term management of EoE.

At week 52, histologic remission was observed in 67.8% of patients receving the 210 mg dose and 63.3% receiving the 420 mg dose. The corresponding remission rate in the placebo group was 5.4%.
Improvements in swallowing symptoms were also maintained. The average Dysphagia Symptom Questionnaire score decreased by 22.1 points with the 210 mg points with the 420 mg dose, compared with a 13.2-point reduction in the placebo group.

The trial also evaluated endoscopic remission, which assesses visible signs of inflammation and structural changes in the esophagus. At week 52, 34.4 % of patients receiving the 210 mg dose and 29.5% receiving the 420 mg dose achieved total endoscopic remission, compared with 4.1% in the placebo group.

These findings are significant because EoE can affect several aspects of esophageal health. Persistent inflammation may contribute to tissue changes, narrowing of the esophagus, and difficulties swallowing food. Improvements across histologic, symptomatic, and endoscopic measures could therefore provide a more comprehensive picture of treatment response. 

Understanding the Unmet Need in Eosinophilic Esophagitis

Eosinophilic esophagitis is a chronic inflammatory disorder affecting the esophagus, the tube that carries food from the mouth to the stomach. The condition involves an abnormal inflammatory response that can interfere with normal swallowing and eating.

Common symptoms include difficulty or pain when swallowing, food becoming stuck in the esophagus, nausea, and vomiting. In severe cases, food impaction may require emergency medical attention. These symptoms can affect daily activities, dietary choices, and overall quality of life.

Current treatment approaches include proton pump inhibitors, swallowed topical corticosteroids, and dietary modification. Although these options can help control symptoms and inflammation, some patients do not achieve adequate disease control.

According to the companies, nearly half of patients may continue to experience inadequately controlled symptoms despite standard treatment approaches. This creates an opportunity for therapies that target different mechanisms involved in the disease.

The CROSSING results could be particularly relevant for patients who continue to experience. However, further regulatory evaluation will be necessary before TEZPIRE can be considered an approved treatment option for EoE.

How TEZPIRE Targets Inflammation

TEZPIRE is a monoclonal antibody that targets thymic stromal lymphopoietin (TSLP), an epithelial cytokine involved in initiating multiple inflammatory pathways. By blocking TSLP, the medicine is designed to reduce inflammatory signaling associated with several conditions.

This mechanism distinguishes TEZPIRE from treatments that primarily focus in managing symptoms or suppressing inflammation through other pathways. Because TSLP can contribute to broader inflammatory responses, targeting it may offer potential benefits across different epithelial-driven inflammatory diseases.

TEZPIRE is already approved for certain patients with severe asthma and chronic rhinosinusitis with nasal polyps in specified markets. Its investigation in EoE represents an extension of research into the role of TSLP inhibition in other inflammatory conditions.

Nevertheless, positive clinical trial findings should not be interpreted as confirmation of approval or established effectiveness in every patient group. Regulatory authorities will need to evaluate the full evidence before determining whether the medicine can be used for EoE.

Safety Profile and Future Development

The companies reported that TEZPIRE’s safety profile in the CROSSING trial was consistent with its established approved indications. The most frequently reported adverse events in the study included nasopharyngitis, headache, and diarrhea.

Safety evaluation remains an important part of biologic drug development, particularly when a treatment is intended for chronic conditions requiring repeated administration. Future assessment of clinical evidence, potential risks, and long-term outcomes will help determine the medicine's future role in EoE management.

The full cross-over trial results are scheduled for presentation at United  European Gastroenterology Week 2026 in Barcelona, Spain. The findings may provide additional information for clinicians and researchers evaluating emerging treatment strategies for this condition.

Conclusion

Amgen and AstraZeneca’s positive Phase 3 CROSSING trial results position TEZPIRE as a promising investigational approach for eosinophilic esophagitis. Sustained improvements in histologic remission, swallowing symptoms, and endoscopic outcomes through 52 weeks highlight its potential to address multiple dimensions of the disease.

The finding also reflects a broader pharmaceutical industry trend toward targeted biologic therapies designed to address underlying inflammatory mechanisms rather than symptoms alone. For patients who remain inadequately controlled with existing treatment, this research could represent an important development.

However, the long-term clinical and commercial impact will depend on regulatory review, additional evidence, and the medicines' eventual place within treatment guidelines. If approved for EoE, TEZPIRE could broaden the options available to patients and healthcare professionals managing this chronic gastrointestinal condition.